Ray Adrian S, Basavapathruni Aravind, Anderson Karen S
Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
J Biol Chem. 2002 Oct 25;277(43):40479-90. doi: 10.1074/jbc.M205303200. Epub 2002 Aug 9.
Abacavir has been shown to select for multiple resistant mutations in the human immunodeficiency type 1 (HIV-1) pol gene. In an attempt to understand the molecular mechanism of resistance in response to abacavir, and nucleoside analogs in general, a set of reverse transcriptase mutants were studied to evaluate their kinetics of nucleotide incorporation and removal. It was found that, similar to the multidrug-resistant mutant reverse transcriptase (RT)(Q151M), the mutations L74V, M184V, and a triple mutant containing L74V/Y115F/M184V all caused increased selectivity for dGTP over the active metabolite of abacavir (carbovir triphosphate). However, the magnitude of resistance observed in cell culture to abacavir in previous studies was less than that observed to other compounds. Our mechanistic studies suggest that this may be due to carbovir triphosphate decreasing the overall effect on its efficiency of incorporation by forming strong hydrophobic interactions in the RT active site. Unlike RT(AZTR), no increase in the rate of ATP- or PP(i)-mediated chain terminator removal relative to RT(WT) could be detected for any of the mutants. However, marked decreases in the steady-state rate may serve as a mechanism for increased removal of a chain-terminating carbovir monophosphate by increasing the time spent at the primer terminus for some of the mutants studied. The triple mutant showed no advantage in selectivity over RT(M184V) and was severely impaired in its ability to remove a chain terminator, giving no kinetic basis for its increased resistance in a cellular system. Biochemical properties including percentage of active sites, fidelity, and processivity may suggest that the triple mutant's increased resistance to abacavir in cell culture is perhaps due to a fitness advantage, although further cellular studies are needed to verify this hypothesis. These data serve to further the understanding of how mutations in RT confer resistance to nucleoside analogs.
已证明阿巴卡韦会导致人类免疫缺陷病毒1型(HIV-1)的多聚酶基因中出现多种耐药性突变。为了了解对阿巴卡韦以及一般核苷类似物产生耐药性的分子机制,研究了一组逆转录酶突变体,以评估它们掺入和去除核苷酸的动力学。结果发现,与多药耐药突变体逆转录酶(RT)(Q151M)类似,L74V、M184V突变以及包含L74V/Y115F/M184V的三重突变体均导致对dGTP的选择性高于阿巴卡韦的活性代谢物(三磷酸卡波韦)。然而,在之前的研究中,细胞培养中观察到的对阿巴卡韦的耐药程度低于对其他化合物的耐药程度。我们的机制研究表明,这可能是因为三磷酸卡波韦通过在RT活性位点形成强疏水相互作用,降低了对其掺入效率的总体影响。与RT(AZTR)不同,对于任何突变体,相对于RT(野生型),均未检测到ATP或PP(i)介导的链终止剂去除速率增加。然而,稳态速率的显著降低可能是某些研究的突变体通过增加在引物末端停留的时间来增加链终止卡波韦单磷酸去除的一种机制。三重突变体在选择性上相对于RT(M184V)没有优势,并且其去除链终止剂的能力严重受损,这为其在细胞系统中增加的耐药性提供不了动力学依据。包括活性位点百分比、保真度和持续合成能力在内的生化特性可能表明,三重突变体在细胞培养中对阿巴卡韦增加的耐药性可能是由于适应性优势,尽管需要进一步的细胞研究来验证这一假设。这些数据有助于进一步理解RT中的突变如何赋予对核苷类似物的耐药性。